Advisory Research Inc Ironwood Pharmaceuticals Inc Transaction History

Advisory Research Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$10.1 - $11.6 $12,665 - $14,546	1,254 Added 4.24%	30,854 $328,000
Q1 2023 May 12, 2023	SELL	$10.37 - $12.56 $7,186 - $8,704	-693 Reduced 2.29%	29,600 $311,000
Q4 2022 Feb 13, 2023	SELL	$9.9 - $12.43 $435 - $546	-44 Reduced 0.15%	30,293 $375,000
Q3 2022 Nov 14, 2022	BUY	$10.14 - $12.38 $2,058 - $2,513	203 Added 0.67%	30,337 $314,000
Q2 2022 Aug 17, 2022	BUY	$11.05 - $12.72 $332,980 - $383,304	30,134 New	30,134 $347,000

237

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $679M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.